Clinical trials: Advanced Solid Malignancy
Colorectal Cancer, Esophageal Cancer
Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00019513
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Solid Tumor, Adult, BRCA1 Mutation
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
The purpose of this study is to determine if the experimental treatment with poly-ADP ribose polymerase (PARP) inhibitor, ACE-86225106 is safe, tolerable and has anti-cancer activity in adult patients with advanced solid tumors.
- Conditions
- Solid Tumor, Adult, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer
- Trial name
- NCT06380660
- Testing
- ACE-86225106 tablet
- Where
- 14 sites in China
- Volunteers
- 298 people
- Sponsor
- Acerand Therapeutics (Shanghai) Limited
Malignant Solid Tumor
ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan
Evaluation of the safety, tolerability and pharmacokinetics (PK) of a single dose and multiple doses of ONO-4538 in Japanese patients with advanced malignant solid tumors, and exploratory evaluation of the pharmacological effect…
- Trial name
- NCT00836888
- Testing
- ONO-4538
- Where
- Japan
- Volunteers
- 17 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Lymphoma, Non-Hodgkin
Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
CC-95775-ST-001 is an open-label, Phase 1B, dose escalation and expansion study of CC-95775 in subjects with advanced or unresectable solid tumors, including laBCC, and relapsed/ refractory non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT04089527
- Testing
- CC-95775
- Where
- 5 sites in France, Spain
- Volunteers
- 24 people
- Sponsor
- Celgene
Advanced or Metastatic Solid Tumor
The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors
This is a phase 1, open-label, single-arm study in Chinese patients with unresectable, locally advanced or metastatic solid tumor with KRAS G12C mutation, for which treatment with curative intent is not available.
- Trial name
- NCT05263986
- Testing
- MRTX849
- Where
- 8 sites in China
- Volunteers
- 22 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Advanced Solid Tumors
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors
The study is being conducted to evaluate the safety, tolerability and pharmacokinetics of HRS-3802 monotherapy in patients with malignant solid tumors.
- Trial name
- NCT06770569
- Testing
- HRS-3802
- Where
- 6 sites in Australia, China
- Volunteers
- 100 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Advanced Solid Tumors
A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation
This study is to evaluate the safety, tolerability, PK, and preliminary efficacy of NTS071 in adults with TP53 Y220C-mutated solid tumors.
- Trial name
- NTS071 (NCT07060989)
- Testing
- NTS071
- Where
- 10 sites in United States, China
- Volunteers
- 220 people
- Sponsor
- Nutshell Therapeutics (Shanghai) Co., LTD.
Cancer
A Study of LY2584702 in Solid Tumors
The purpose of this study is to assess the safety and tolerability of LY2584702 in Japanese patients with advanced and/or metastatic solid tumors for which no proven effective therapy exists.
- Trial name
- NCT01241461
- Testing
- LY2584702
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumors
Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy
M3814 was an investigational drug that is being evaluated for the treatment of participants with locally advanced tumors. The main purposes of this study was to determine the safety, the tolerability and the efficacy of M3814 in…
- Trial name
- NCT02516813
- Testing
- M3814 100 mg, M3814 200 mg, M3814 300 mg
- Where
- 26 sites in United States, Belgium and 6 more
- Volunteers
- 52 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Solid Cancers
A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors
This is a Phase Ib, open-label, dose-escalation study of MNRP1685A given by intravenous (IV) infusion as therapy for locally advanced or metastatic solid tumors.
- Trial name
- NCT00954642
- Testing
- bevacizumab, MNRP1685A, paclitaxel
- Volunteers
- 24 people
- Sponsor
- Genentech, Inc.
Advanced Malignant Solid Tumor
Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden
CAPTURE is a prospective, interventional, randomized, phase 2, double-blind, placebo-controlled study assessing the therapeutic add-on effect of the balanced THC/CBD extract (Cannabis extract Avextra 10/10 oral solution) on…
- Trial name
- CAPTURE (NCT07459920)
- Testing
- Cannabis Extract Oil
- Where
- Italy
- Volunteers
- 156 people
- Sponsor
- National Cancer Institute, Naples
Colorectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine, irinotecan, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00296062
- Testing
- bevacizumab, capecitabine, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Case Comprehensive Cancer Center
Solid Tumor, Metastatic Tumor
A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors
A Phase 1 dose escalation study to determine if axatilimab as monotherapy and axatilimab in combination with a fixed dose of durvalumab will be sufficiently safe and well-tolerated at biologically active doses to warrant further…
- Conditions
- Solid Tumor, Metastatic Tumor, Locally Advanced Malignant Neoplasm, Unresectable Malignant Neoplasm
- Trial name
- NCT03238027
- Testing
- Axatilimab, Durvalumab
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Syndax Pharmaceuticals
Neoplasms
A Study of NM-3 Administered Orally in Patients With Advanced Solid Tumors.
A study for patients who have failed standard therapy. If there is no dose limiting toxicities the patients will receive further cycles of therapy if there is no evidence of disease progression.
- Trial name
- NCT00046696
- Testing
- NM-3
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Genzyme, a Sanofi Company
Advanced/Metastatic Malignant Solid Tumors
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors
This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX43 in patients with advanced/metastatic solid tumors.
- Trial name
- NCT06115642
- Testing
- HLX43, HLX10
- Where
- 14 sites in United States, China and 1 more
- Volunteers
- 367 people
- Sponsor
- Shanghai Henlius Biotech
Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and toripalimab) for the treatment of participants with unresectable, locally advanced, or metastatic solid tumors…
- Conditions
- Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT07623642
- Testing
- GV20-0251, anti-PD-1 monoclonal antibodies
- Where
- 2 sites in China
- Volunteers
- 227 people
- Sponsor
- GV20 Therapeutics
Solid Tumor
A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors
This include two parts, part 1 is a dose escalation study and part 2 is a dose expansion study.
- Trial name
- NCT05369286
- Testing
- "MAX-40279-01" and "Toripalimab"
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Maxinovel Pty., Ltd.
Solid Tumors
A Dose Escalating Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer
A dose escalating phase Ia-b clinical trial of the IGF-1 receptor inhibitor AXL1717 in patients with advanced cancer. The objective is to study the safety and pharmacokinetics of AXL1717 and to define an appropriate Phase 2 dose…
- Trial name
- NCT01062620
- Testing
- AXL1717
- Where
- Sweden
- Volunteers
- 49 people
- Sponsor
- Axelar AB
Advanced Malignant Solid Tumor
Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors
The purpose of this study is to see the safety and efficient of neoantigen reactive T cells (NRTs) combined with programmed cell death-1(PD-1) inhibitor（SHR-1210）in the treatment of Chinese patients with advanced refractory solid…
- Trial name
- NRT-01 (NCT03171220)
- Testing
- Neoantigen Reactive T Cells(NRTs), SHR-1210, Fludarabine
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.